Denis Guttridge to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Denis Guttridge has written about Xenograft Model Antitumor Assays.
Connection Strength
0.131
-
Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.034
-
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
Score: 0.034
-
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 02; 16(2):344-356.
Score: 0.032
-
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther. 2016 05; 15(5):1018-28.
Score: 0.031